Evidence map›Paper›PMID 38170519›Full record

ArticleJAMA network open2024

Inpatient Costs of Treating Patients With COVID-19.

Kandice A Kapinos, Richard M Peters, Robert E Murphy, Samuel F Hohmann, Ankita Podichetty, Raymond S Greenberg

Abstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Economic evaluation of wastewater surveillance in Ontario, Canada, using COVID-19 as a case study.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026
    Article
  5. Observational
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Economic Burden of COVID-19 Hospitalization in Almaty, Kazakhstan.ClinicoEconomics and outcomes research : CEOR · 2026
    Article
  12. Observational
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kandice A KapinosRAND Corporation, Arlington, Virginia.
Richard M PetersDepartment of Population Health, Dell Medical School, The University of Texas at Austin.
Robert E MurphySchool of Biomedical Informatics, The University of Texas Health Science Center at Houston.
Samuel F HohmannVizient, Chicago, Illinois.
Ankita PodichettySchool of Biomedical Informatics, The University of Texas Health Science Center at Houston.
Raymond S GreenbergPeter O'Donnell Jr. School of Public Health, The University of Texas Southwestern Medical Center, Dallas.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: With more than 6.2 million hospitalizations due to COVID-19 in the US, recognition of the average hospital costs to provide inpatient care during the pandemic is necessary to understanding the national medical resource use and improving public health readiness and related policies. Objective: To examine the mean cost to provide inpatient care to treat COVID-19 and how it varied through the pandemic waves and by important sociodemographic patient characteristics. Design, Setting, and Participants: This cross-sectional study used inpatient-level data from March 1, 2020, to March 31, 2022, extracted from a repository of clinical, administrative, and financial information covering 97% of academic medical centers across the US. Main Outcomes and Measures: Cost to produce care for each stay was calculated using direct hospital costs to provide care adjusted for geographic differences in labor costs using area wage indices. Results: The sample included 1 333 404 stays with a primary or secondary COVID-19 diagnosis from 841 hospitals. The cohort included 692 550 (52%) men, with mean (SD) age of 59.2 (17.5) years. The adjusted mean cost of an inpatient stay was $11 275 (95% CI, $11 252-$11 297) overall, increasing from $10 394 (95% CI, $10 228-$10 559) at the end of March 2020 to $13 072 (95% CI, $12 528-$13 617) by the end of March 2022. Patients with specific comorbidities had significantly higher mean costs than their counterparts: those with obesity incurred an additional $2924 in inpatient stay costs, and those with coagulation deficiency incurred an additional $3017 in inpatient stay costs. Stays during which the patient required extracorporeal membrane oxygenation (ECMO) had an adjusted mean cost of $36 484 (95% CI, $34 685-$38 284). Conclusions and Relevance: In this cross-sectional study, an adjusted mean hospital cost to provide care for patients with COVID-19 increased more than 5 times the rate of medical inflation overall. This appeared to be explained partly by changes in the use of ECMO, which increased over time.

Indexed as

COVID-19InpatientsCOVID-19 TestingCross-Sectional StudiesFemaleHospitalizationHumansMaleMiddle Aged

Identifiers

PMID38170519
PMCPMC10765267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.